p53通过TSC2/TFEB依赖的衰老程序驱动肺癌消退
该研究利用小鼠和人类模型解析肺腺癌中p53治疗反应的转录程序及后续事件。研究发现p53通过直接反式激活Tsc2抑制mTORC1并促使TFEB核积累,进而触发溶酶体基因表达、自噬和细胞衰老,衰老细胞分泌因子招募巨噬细胞介导癌细胞吞噬和肿瘤消退。
要点
- p53通过直接反式激活Tsc2抑制mTORC1,诱导TFEB核积累。
- TFEB核积累触发溶酶体基因表达、自噬和细胞衰老程序。
- 衰老肺腺癌细胞分泌因子招募巨噬细胞,促进癌细胞吞噬和肿瘤消退。
核心结论
- p53通过TSC2-mTORC1-TFEB轴驱动衰老程序,进而引发巨噬细胞介导的吞噬和肺腺癌消退。
研究设计与样本
- 研究使用小鼠和人类模型解构肺腺癌中稳健治疗反应背后的转录程序及后续事件。
主要发现
- p53直接反式激活Tsc2,导致mTORC1抑制和TFEB核积累。
- TFEB核积累触发溶酶体基因表达程序、自噬和细胞衰老。
- 衰老肺腺癌细胞分泌因子招募巨噬细胞, precipitating癌细胞吞噬和肿瘤消退。
临床怎么用
- 研究揭示了p53治疗反应中可靶向的节点,为优化基于p53的联合治疗提供关键框架。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Pharmacologic restoration of p53 tumor suppressor function is a conceptually appealing therapeutic strategy for the many deadly cancers with compromised p53 activity, including lung adenocarcinoma. However, the p53 pathway has remained undruggable, partly because of insufficient understanding of how to drive effective therapeutic responses without toxicity. In this study, we use mouse and human models to deconstruct the transcriptional programs and sequelae underlying robust therapeutic responses in lung adenocarcinoma. We show that p53 drives potent tumor regression by direct Tsc2 transactivation, leading to mTORC1 inhibition and Transcription factor EB (TFEB) nuclear accumulation, which in turn triggers lysosomal gene expression programs, autophagy, and cellular senescence. Senescent lung adenocarcinoma cells secrete factors to recruit macrophages, precipitating cancer cell phagocytosis and tumor regression. Collectively, our analyses reveal a surprisingly complex cascade of events underlying a p53 therapeutic response in lung adenocarcinoma and illuminate targetable nodes for p53 combination therapies, thus establishing a critical framework for optimizing p53-based therapeutics. SIGNIFICANCE: Cancer therapies based on targeting the p53 pathway remain elusive. To address this gap, we unravel the detailed sequence of events governing p53-induced tumor regression in lung adenocarcinoma. These analyses reveal a TSC2-mTORC1-TFEB axis underlying p53-driven senescence and tumor regression, which suggests new strategies to perfect p53-based combination therapies for lung adenocarcinoma.
引用
- Wang M, Bieging-Rolett KT, Kaiser AM, et al. p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program. Cancer Discov. 2026. PMID: 41115251. doi:10.1158/2159-8290.CD-25-0525
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。